1.The Effects of On-site Measured Ozone Concentration on Pulmonary Function and Symptoms of Asthmatics.
Doh Hyung KIM ; Youn Seup KIM ; Jae Seuk PARK ; Ho Jang KWON ; Kye Young LEE ; Sang Rok LEE ; Young Koo JEE
Journal of Korean Medical Science 2007;22(1):30-36
Most studies on the effects of ambient ozone on asthmatics have been based on ozone concentration measurements taken by air monitors in downtown areas. Using a passive ozone sampler, we investigated the effects of on-site ozone concentrations on the pulmonary function and symptoms of asthmatics. Twenty moderate to severe asthmatics who had been managed for at least 2 months without changes of their medication were enrolled from 3 June to 18 July 2005. Respiratory, nasal and ocular symptoms, peak expiratory flow (PEF), which was measured twice a day, and medication use were recorded on a daily basis during the study period. Data for 17 subjects were analyzed. The average ozone exposure level was 28.2+/-23.6 ppb (3.4-315.3 ppb). There was no significant correlation between PEF and ozone concentration (p>0.05) on the same day or 1-, 2-, or 3-day lags. Interestingly, the degree of asthma symptoms was influenced by the ozone concentration (rho=0.303, p<0.001), even at concentrations less than 80 ppb (p=0.298, p<0.001), but the correlation between ozone exposure and the frequency of reliever medication use was not statistically significant (p=0.99). Our results suggest that exposure to relatively low concentrations of ozone influences the symptoms of moderate to severe asthmatics regardless of changes in pulmonary function or medication use.
Ozone/analysis/*toxicity
;
Nebulizers and Vaporizers
;
Middle Aged
;
Male
;
Lung/*physiopathology
;
Humans
;
Female
;
Asthma/drug therapy/*etiology/physiopathology
;
Air Pollution/*adverse effects
;
Aged
;
Adult
3.Exercise induced asthma.
Yun-chun LUO ; Qiang-wei XIANG
Chinese Journal of Pediatrics 2005;43(6):423-425
Anti-Asthmatic Agents
;
therapeutic use
;
Asthma, Exercise-Induced
;
diagnosis
;
epidemiology
;
physiopathology
;
therapy
;
Child
;
Constriction, Pathologic
;
drug therapy
;
etiology
;
physiopathology
;
Diagnosis, Differential
;
Glucocorticoids
;
therapeutic use
;
Humans
;
Risk Factors
;
Treatment Outcome
4.Regulation of pro-inflammatory responses by lipoxygenases via intracellular reactive oxygen species in vitro and in vivo.
So Yong KIM ; Tae Bum KIM ; Keun Ai MOON ; Tae Jin KIM ; Dongwoo SHIN ; You Sook CHO ; Hee Bom MOON ; Ki Young LEE
Experimental & Molecular Medicine 2008;40(4):461-476
Reactive oxygen species (ROS) performs a pivotal function as a signaling mediator in receptor-mediated signaling. However, the sources of ROS in this signaling have yet to be determined, but may include lipoxygenases (LOXs) and NADPH oxidase. The stimulation of lymphoid cells with TNF-alpha, IL-1beta, and LPS resulted in significant ROS production and NF-kappaB activation. Intriguingly, these responses were markedly abolished via treatment with the LOXs inhibitor nordihydroguaiaretic acid (NDGA). We further examined in vivo anti-inflammatory effects of NDGA in allergic airway inflammation. Both intraperitoneal and intravenous NDGA administration attenuated ovalbumin (OVA)-induced influx into the lungs of total leukocytes, as well as IL-4, IL-5, IL-13, and TNF-alpha levels. NDGA also significantly reduced serum levels of OVA-specific IgE and suppressed OVA-induced airway hyperresponsiveness to inhaled methacholine. The results of our histological studies and flow cytometric analyses showed that NDGA inhibits OVA-induced lung inflammation and the infiltration of CD11b+ macrophages into the lung. Collectively, our findings indicate that LOXs performs an essential function in pro-inflammatory signaling via the regulation of ROS regulation, and also that the inhibition of LOXs activity may have therapeutic potential with regard to the treatment of allergic airway inflammation.
Animals
;
Antioxidants/metabolism
;
Asthma/complications/metabolism/pathology/physiopathology
;
Bronchial Hyperreactivity/drug therapy/pathology
;
Bronchial Provocation Tests
;
Bronchoalveolar Lavage Fluid/cytology
;
Cells, Cultured
;
Drug Evaluation, Preclinical
;
Humans
;
Inflammation/*etiology/metabolism
;
Jurkat Cells
;
Lipoxygenase/*physiology
;
Lipoxygenase Inhibitors/pharmacology/therapeutic use
;
Lymphocytes/drug effects/metabolism
;
Male
;
Mice
;
Mice, Inbred BALB C
;
Nordihydroguaiaretic Acid/pharmacology/therapeutic use
;
Reactive Oxygen Species/*adverse effects/*metabolism